Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Dec 04, 2022 1:58pm
186 Views
Post# 35149616

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CG Oncology NMIBC data

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CG Oncology NMIBC data

No problem Apophis...glad at least you were entertained.
 

A small clarification/edit to my explanation:

"If a patient were to remain a PR/IR, I would consider continuing treatments every 3 to 6 months (barring serious side effects/adverse events) until either a CR or NR is achieved."

Would substitute yellow highlighted comment with the blue one....or until progressive disease."

There's the chance that a % of those with stable/stubborn disease or unchanged CIS could potentially convert to CR at some point.  Also, many elderly folk have elderly immune responses & some could certainly need an extra kick or two in the bladder to boost their response/immunity.  My wife would say this elderly trait also applies to my personal life when it comes to taking out the trash.

 

<< Previous
Bullboard Posts
Next >>